Ludimila Cavalcante
Overview
Explore the profile of Ludimila Cavalcante including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
26
Citations
99
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Chandora K, Chandora A, Saeed A, Cavalcante L
Cancers (Basel)
. 2025 Feb;
17(3).
PMID: 39941782
MAGE A4 (Melanoma Antigen Gene A4) is a cancer testis antigen (CTA) that is expressed normally in germline cells (testis/embryonic tissues) but absent in somatic cells. The MAGE A4 CTA...
2.
Michelon I, Castro C, Madeira T, Dacoregio M, Stecca C, Soares L, et al.
Cancer Treat Rev
. 2025 Jan;
133:102882.
PMID: 39805165
Background: Trastuzumab deruxtecan (T-DXd) has shown promising activity in patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer (BC) and central nervous system (CNS) involvement. In this updated...
3.
Priantti J, Fujiwara Y, de Moraes F, Michelon I, Castro C, Leighl N, et al.
JCO Precis Oncol
. 2024 Nov;
8:e2400331.
PMID: 39576954
Purpose: The activity of osimertinib is not fully characterized in non-small-cell lung cancer (NSCLC) with uncommon epidermal growth factor receptor () mutations. Therefore, we conducted a systematic review and meta-analysis...
4.
Michelon I, Dacoregio M, Vilbert M, Priantti J, Ernesto do Rego Castro C, Vian L, et al.
Ther Adv Med Oncol
. 2024 Nov;
16:17588359241297079.
PMID: 39574495
Background: Until recently, targeted therapies have failed to benefit patients with human epidermal growth factor receptor 2 (HER2)-low-expressing breast cancer (BC). Nevertheless, antibody-drug conjugates (ADCs) have reshaped their prognosis. Objectives:...
5.
Cavalcante L, Chandana S, Lakhani N, Enstrom A, LeBlanc H, Schmalz J, et al.
J Immunother Cancer
. 2024 Aug;
12(8).
PMID: 39142718
Engagement of programmed death-1 (PD-1) and cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) can interfere with the CD28 signaling requisite for T-cell activation. While immune checkpoint inhibitors (ICIs) can relieve this suppression,...
6.
Davar D, Cavalcante L, Lakhani N, Moser J, Millward M, McKean M, et al.
J Immunother Cancer
. 2024 Aug;
12(8).
PMID: 39097413
Background: Davoceticept (ALPN-202) is an Fc fusion of a CD80 variant immunoglobulin domain designed to mediate programmed death-ligand 1 (PD-L1)-dependent CD28 co-stimulation while inhibiting the PD-L1 and cytotoxic T-lymphocyte-associated antigen...
7.
Michelon I, Vilbert M, Ernesto do Rego Castro C, Stecca C, Dacoregio M, Rizzo M, et al.
J Pers Med
. 2024 Jul;
14(7).
PMID: 39064005
We performed a systematic review and meta-analysis to assess the efficacy of EGFR-tyrosine kinase inhibitors (TKI) retreatment in advanced/metastatic non-small-cell lung cancer (NSCLC) patients. We systematically searched PubMed, Embase, Cochrane...
8.
Priantti J, Vilbert M, de Moraes F, Madeira T, de Lima Santiago E, Leighl N, et al.
Cancers (Basel)
. 2024 Jul;
16(14).
PMID: 39061249
Lorlatinib has been FDA-approved as a systemic therapy for ALK/ROS1-positive non-small cell lung cancer (NSCLC) patients. However, it has been associated with an increased frequency of neurocognitive adverse events (NAEs)....
9.
Yasinzai A, Tareen B, Tracy K, Jamil N, Khan M, Ullah H, et al.
Clin Transl Oncol
. 2024 Apr;
26(10):2618-2628.
PMID: 38615292
Introduction: Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive malignancy about 50% of PDAC are metastatic at presentation. In this study, we evaluated PDAC demographics, annual trend analysis, racial disparities,...
10.
Khateeb S, Cavalcante L, Alnairat N, Singh M, Sahin I, Saeed A, et al.
Curr Treat Options Oncol
. 2024 Feb;
25(4):496-509.
PMID: 38372852
This paper shines a light on the exciting progress being made in using immunotherapy to treat advanced gastroesophageal cancers. The positive results from trials using drugs like Pembrolizumab and Nivolumab...